Combining oncolytic virotherapy and tumour vaccination

被引：30

作者：

Bridle, Byram W. ^{[1
]}

Hanson, Stephen ^{[1
]}

Lichty, Brian D. ^{[1
]}

机构：

[1] McMaster Univ, Dept Pathol & Mol Med, Ctr Gene Therapeut, Hamilton, ON L8N 3Z5, Canada

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2010年 / 21卷 / 2-3期

关键词：

Oncolytic virus; Tumour vaccine; Prime: boost; Anti-tumour immunity; POTENT ANTITUMOR IMMUNITY; HERPES-SIMPLEX-VIRUS; REGULATORY T-CELLS; PROSTATIC ACID-PHOSPHATASE; VESICULAR STOMATITIS-VIRUS; RECOMBINANT VACCINIA VIRUS; DENDRITIC CELLS; CANCER-PATIENTS; DIVERSIFIED PRIME; COLORECTAL-CANCER;

D O I：

10.1016/j.cytogfr.2010.02.009

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The interactions between the immune system, a malignant tumour and an oncolytic virus are complex and poorly understood. For oncolytic viruses to become successful therapeutics we need to better understand these interactions and identify strategies to take advantage of defects in the innate immune response within tumours and avoid cellular anti-viral responses while capitalizing on anti-tumoural immunity. In this review we will discuss the evidence for the induction of tumour-specific immune responses by oncolytic viruses as well as by cancer vaccines. We will then describe some of the barriers to successful cancer immunotherapy, and finally we will outline a strategy for enhancing anti-tumoural immunity while reducing anti-viral immunity by combining tumour vaccination with oncolytic viral therapy. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：143 / 148

页数：6

共 79 条

[1] Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial [J].

Amato, Robert J. ;

Shingler, William ;

Naylor, Stuart ;

Jac, Jaroslaw ;

Willis, James ;

Saxena, Somyata ;

Hernandez-McClain, Joan ;

Harrop, Richard .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7504-7510

[2] The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].

Bennett, CL ;

Christie, J ;

Ramsdell, F ;

Brunkow, ME ;

Ferguson, PJ ;

Whitesell, L ;

Kelly, TE ;

Saulsbury, FT ;

Chance, PF ;

Ochs, HD .

NATURE GENETICS, 2001, 27 (01) :20-21

[3] Regulatory T Cells: Major Players in the Tumor Microenvironment [J].

Beyer, Marc ;

Schultze, Joachim L. .

CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (16) :1879-1892

[4] Immunotherapeutic strategies in kidney cancer - when TKIs are not enough [J].

Biswas, Swethajit ;

Eisen, Tim .

NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (08) :478-487

[5] Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity [J].

Boudreau, Jeanette E. ;

Bridle, Byram W. ;

Stephenson, Kyle B. ;

Jenkins, Kristina M. ;

Brunelliere, Jerome ;

Bramson, Jonathan L. ;

Lichty, Brian D. ;

Wan, Yonghong .

MOLECULAR THERAPY, 2009, 17 (08) :1465-1472

[6] Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse [J].

Brunkow, ME ;

Jeffery, EW ;

Hjerrild, KA ;

Paeper, B ;

Clark, LB ;

Yasayko, SA ;

Wilkinson, JE ;

Galas, D ;

Ziegler, SF ;

Ramsdell, F .

NATURE GENETICS, 2001, 27 (01) :68-73

[7] Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer:: A phase 2 trial [J].

Burch, PA ;

Croghan, GA ;

Gastineau, DA ;

Jones, LA ;

Kaur, JS ;

Kylstra, JW ;

Richardson, RL ;

Valone, FH ;

Vuk-Pavlovic, S .

PROSTATE, 2004, 60 (03) :197-204

[8]

Carmichael M. G., 2009, CANCER

[9] Combination of Viral Oncolysis and Tumor-Specific Immunity to Control Established Tumors [J].

Chuang, Chi-Mu ;

Monie, Archana ;

Wu, Annie ;

Pai, Sara I. ;

Hung, Chien-Fu .

CLINICAL CANCER RESEARCH, 2009, 15 (14) :4581-4588

[10] Role of transforming growth factor β in cancer microenvironment [J].

de la Cruz-Merino, Luis ;

Henao-Carrasco, Fernando ;

Garcia-Manrique, Teresa ;

Fernandez-Salguero, Pedro M. ;

Codes-Manuel de Villena, Manuel .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11) :715-720

← 1 2 3 4 5 6 7 8 →